Patents Represented by Attorney, Agent or Law Firm Richard P. Ryan
  • Cerebral function enhancing diazinylpiperidine derivatives
    Patent number: 4826843
    Abstract: A series of diazinylpiperidine compounds of Formula I ##STR1## wherein X is an ethylene chain or a 1,2-benzo ring; Y is carbonyl or methylene; R.sup.1 is hydrogen or lower alkyl; and Z is an R.sup.2, R.sup.3 -disubstituted diazinyl ring selected from pyridazine, pyrimidine, and pyrazine ring systems. Pharmacologic and neuroanatomical testing demonstrates that compounds of the series act to enhance cerebral function in mammals, particularly when there is a deficit in normal cerebral functioning. Specific pharmacologic test results indicate that compounds of Formula I possess cognition and memory enhancing activity.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: May 2, 1989
    Assignee: Bristol-Myers
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Michael S. Eison
  • Anti-emetic quinuclidinyl benzamides
    Patent number: 4820715
    Abstract: Novel substituted benzamides of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined herein are useful in the treatment of emesis, and particularly chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility.
    Type: Grant
    Filed: May 18, 1987
    Date of Patent: April 11, 1989
    Assignee: Bristol-Myers Company
    Inventors: Ivo Monkovic, David Willner
  • Process for buspirone hydrochloride polymorphic crystalline form conversion
    Patent number: 4810789
    Abstract: A process for conversion of one polymorphic crystalline form of buspirone into its other polymorphic crystalline form.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: March 7, 1989
    Assignee: Bristol-Myers Company
    Inventors: Robert J. Behme, Terry T. Kensler, Douglas G. Mikolasek
  • Pharmacologically active substituted benzamides
    Patent number: 4808624
    Abstract: Novel substituted benzamides of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined herein are useful in the treatment of emesis, and particularly chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility.
    Type: Grant
    Filed: May 6, 1985
    Date of Patent: February 28, 1989
    Assignee: Bristol-Myers Company
    Inventors: Ivo Monkovic, David Willner
  • Process intermediate for the preparation of encainide
    Patent number: 4800226
    Abstract: A novel dimethylsulfate quaternary salt process intermediate useful in the manufacture of the antiarrhythmic agent encainide.
    Type: Grant
    Filed: April 20, 1987
    Date of Patent: January 24, 1989
    Assignee: Bristol-Myers Company
    Inventors: John L. Dillon, Richard H. Spector
  • 1,3,4-oxadiazole pyschotropic compounds
    Patent number: 4784998
    Abstract: Psychotropic 1,3,4-oxadiazole compounds and their use as tranquilizers, analgesics and antidepressants.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: November 15, 1988
    Assignee: Bristol-Myers Company
    Inventor: Joseph P. Yevich
  • Gepirone for alleviation of panic disorders
    Patent number: 4782060
    Abstract: Gepirone and its pharmaceutically acceptable salts are useful in alleviation of panic disorders which can take the form of clinical syndromes comprising, for example, panic attacks, agoraphobia and phobic anxiety.
    Type: Grant
    Filed: July 29, 1987
    Date of Patent: November 1, 1988
    Assignee: Bristol-Myers Company
    Inventors: Neil Kurtz, Roger E. Newton, Davis L. Temple, Jr.
  • Method for treatment of alcohol abuse
    Patent number: 4777173
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in the treatment of alcohol abuse.
    Type: Grant
    Filed: March 25, 1987
    Date of Patent: October 11, 1988
    Assignee: Bristol-Myers Company
    Inventors: Rajesh Shrotryia, George P. Casten
  • Method for alleviation of primary depressive disorders
    Patent number: 4771053
    Abstract: Gepirone and its pharmaceutically acceptable salts are useful in alleviation of certain primary depressive disorders, such as major depression with melancholia and atypical depression.
    Type: Grant
    Filed: March 2, 1987
    Date of Patent: September 13, 1988
    Assignee: Bristol-Myers Company
    Inventors: Jerry M. Cott, Neil Kurtz, Donald S. Robinson
  • Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
    Patent number: 4757073
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a substituted pyridin-2-yl ring and the second substituent is a butylene chain attached to cyclic imide heterocycles such as azaspiro[4.5]decanedione, dialkylglutarimide, thiazolidinedione, spirocyclopentylthiazolidinedione, or morpholine-2,6-dione. The compounds have psychotropic properties and 2-[4-[4-(2,4-dioxo-1-thia-3-azaspiro[4.5]nonane-3-yl)butyl]-1-piperazinyl] -pyridine-3-carboxaldehyde is a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: September 30, 1986
    Date of Patent: July 12, 1988
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Walter G. Lobeck, Jr., Joseph P. Yevich
  • Method for improvement of short term memory
    Patent number: 4687772
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in the clinical improvement of short term memory.
    Type: Grant
    Filed: October 7, 1986
    Date of Patent: August 18, 1987
    Assignee: Bristol-Myers Company
    Inventor: Marc T. Alderdice
  • Method for treatment of male impotence
    Patent number: 4687771
    Abstract: Trazodone and its pharmaceutically acceptable salts are useful in the treatment of male sexual impotence.
    Type: Grant
    Filed: November 1, 1985
    Date of Patent: August 18, 1987
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Gamble, Harry L. Hunter, Gordon R. McKinney
  • Antipsychotic fused-ring pyridinylpiperazine derivatives
    Patent number: 4677104
    Abstract: Disubstituted 1,4-piperazinyl derivatives are disclosed wherein one substituent is a bicyclic fused-ring furo-, pyrrolo-, cyclopentadieno-, or thieno-pyridine heterocyclic system and the second substituent is an alkylene chain attached to cyclic imide heterocycles, such as azaspiro[4.5]decanediones, dialkylglutarimides, thiazolidinediones, succinimides, and morpholine-2,6-diones; or a benzylic carbinol moiety. These compounds have potent antipsychotic and serotonin antagonist activities. 4-[4-[4-(4-Furo[3,2-c]pyridinyl)-1-piperazinyl]butyl]-3,5-morpholinedione is an example of a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: July 16, 1986
    Date of Patent: June 30, 1987
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Joseph P. Yevich
  • Process for the preparation of encainide
    Patent number: 4675409
    Abstract: A new and novel process for the preparation of encainide (4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]-benzanilide) has been developed. The process utilizes .alpha.-picoline, O-nitrobenzaldehyde, and anisoyl chloride as starting materials.
    Type: Grant
    Filed: February 25, 1986
    Date of Patent: June 23, 1987
    Assignee: Bristol-Myers Company
    Inventors: John L. Dillon, Richard H. Spector
  • Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
    Patent number: 4668687
    Abstract: A series of nootropic compounds of the following formula: ##STR1## and its pharmaceutically acceptable acid addition salts, wherein: R.sup.2 is hydrogen, lower alkyl, aryl which is optimally substituted, or hetaryl;R.sup.7 is hydrogen or is combined with R.sup.9 as a fused benzo-ring;R.sup.8 is hydrogen or lower alkyl; andR.sup.9 is lower alkyl, or R.sup.9 can be combined with R.sup.8 to give a 2-pyrrolidinone, a phthalimide, or isoindolone ring system.Pharmacological testing demonstrates that the series possesses cognition and memory enhancing actions and/or mild CNS simulation.
    Type: Grant
    Filed: November 19, 1985
    Date of Patent: May 26, 1987
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Yevich, Ronald J. Mattson
  • Antipsychotic benzisothiazole S-oxide compound
    Patent number: 4656173
    Abstract: 8-[4-[4-(1-Oxo-1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5 ]decane-7,9-dione is an antipsychotic agent having reduced side effect liability.
    Type: Grant
    Filed: April 24, 1985
    Date of Patent: April 7, 1987
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Yevich, Walter G. Lobeck, Jr.
  • Treatment of sexual dysfunction with buspirone
    Patent number: 4640921
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in treating patients of both sexes suffering from sexual dysfunction.
    Type: Grant
    Filed: February 4, 1986
    Date of Patent: February 3, 1987
    Assignee: Bristol-Myers
    Inventors: Ekkehard Othmer, Sieglinde C. Othmer
  • Method for alleviation of panic disorders
    Patent number: 4634703
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in alleviation of panic disorders which can take the form of clinical syndromes comprising, for example, panic attacks, agoraphobia and phobic anxiety.
    Type: Grant
    Filed: October 25, 1985
    Date of Patent: January 6, 1987
    Assignee: Bristol-Myers Company
    Inventors: Neil M. Kurtz, Roger E. Newton, Davis L. Temple, Jr.
  • Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
    Patent number: 4619930
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a substituted pyridin-2-yl ring and the second substituent is a butylene chain attached to cyclic imide heterocycles such as azaspiro[4.5]decanedione, dialkylglutarimide, thiazolidinedione, spirocyclopentylthiazolidinedione, or morpholine-2,6-dione. The compounds have psychotropic properties and 2-[4-[4-(2,4-dioxo-1-thia-3-azaspiro[4.5]nonane-3-yl)butyl]-1-piperazinyl] pyridine-3-carboxaldehyde is a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: January 16, 1985
    Date of Patent: October 28, 1986
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Walter G. Lobeck, Jr., Joseph P. Yevich
  • Angiotensin-converting enzyme inhibiting dipeptide derivatives
    Patent number: 4617291
    Abstract: Dipeptides having the formula ##STR1## wherein A is halogen, hydrogen, lower alkyl, or lower alkoxy; B is hydrogen or lower alkyl, or A and B are taken together to form an ortho-methylene or ethylene bridge; R is hydrogen, lower alkyl, or phenylalkyl; and X.sup.1 and X.sup.2 are independently chosen from hydroxy or lower alkoxy; are inhibitors of angiotensin-converting enzyme and can be used for the treatment of hypertension in mammals.
    Type: Grant
    Filed: May 14, 1982
    Date of Patent: October 14, 1986
    Assignee: Mead Johnson & Company
    Inventors: Tellis A. Martin, Terence M. Dolak